Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients. V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, was assessed in two late-stage studies. The PNEU-WAY trial studied the vaccine in adults…
Evelo Stock Soars After Asset Tapped for Phase II/III COVID-19 Study in the U.K.
Shares of Evelo Biosciences were up more than 25% in premarket trading after the company announced its investigational asset EDP1815 will be included in the Phase II/III TACTIC-E COVID-19-focused clinical trial for conducted by Cambridge University Hospitals NHS Foundation Trust.…
Myovant’s Relugolix Combo Hits the Mark in Endometriosis, Heads to FDA for Prostate Cancer
Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis. The drug combination met its co-primary efficacy endpoints as well as all seven key secondary endpoints.…
Faster nod for clinical trials of all drugs and vaccines soon
A committee led by cabinet secretary Rajiv Gauba has also decided to set up a nodal coordination committee to ensure expeditious disposal of all applications with the decision binding on all regulators. “The proposal was cleared by the committee in…
Ministry of Health publishes draft New Drugs and Clinical Trials (Amendment) Rules
The Union Health Ministry has come up with draft New Drugs and Clinical Trials (Amendment) Rules, inserting provisions for “compassionate use” of any unapproved drug that is in the phase-III clinical trial, either in India or abroad, by importing or…
Almac unveils advanced solution to accelerate study start-up
Almac Clinical Technologies, a unit of UK-based contract development and manufacturing firm Almac Group, has introduced an advanced interactive response technology (IRT). ‘Simplify’ is designed to accelerate the study start-up process with higher efficiency and comes with an array of…
Medical device industry to get over ₹3,000 crore boost-Business Journal
Domestic medical devices industry is set to receive a booster dose as central government lays out plan to incentivise Indian players with at least ₹3,420 crore, over a period of five years. This incentive would be provided if they were…
